Literature DB >> 32913180

Ulcerative colitis.

Taku Kobayashi1, Britta Siegmund2, Catherine Le Berre3, Shu Chen Wei4, Marc Ferrante5, Bo Shen6, Charles N Bernstein7, Silvio Danese8, Laurent Peyrin-Biroulet3, Toshifumi Hibi9.   

Abstract

Ulcerative colitis (UC) is a chronic inflammatory bowel disease of unknown aetiology affecting the colon and rectum. Multiple factors, such as genetic background, environmental and luminal factors, and mucosal immune dysregulation, have been suggested to contribute to UC pathogenesis. UC has evolved into a global burden given its high incidence in developed countries and the substantial increase in incidence in developing countries. An improved understanding of the mechanisms underlying UC has led to the emergence of new treatments. Since the early 2000s, anti-tumour necrosis factor (TNF) treatment has significantly improved treatment outcomes. Advances in medical treatments have enabled a paradigm shift in treatment goals from symptomatic relief to endoscopic and histological healing to achieve better long-term outcomes and, consequently, diagnostic modalities have also been improved to monitor disease activity more tightly. Despite these improvements in patient care, a substantial proportion of patients, for example, those who are refractory to medical treatment or those who develop colitis-associated colorectal dysplasia or cancer, still require restorative proctocolectomy. The development of novel drugs and improvement of the treatment strategy by implementing personalized medicine are warranted to achieve optimal disease control. However, delineating the aetiology of UC is necessary to ultimately achieve disease cure.

Entities:  

Mesh:

Year:  2020        PMID: 32913180     DOI: 10.1038/s41572-020-0205-x

Source DB:  PubMed          Journal:  Nat Rev Dis Primers        ISSN: 2056-676X            Impact factor:   52.329


  135 in total

1.  Food for thought about the immune drivers of gut pain.

Authors:  Stuart M Brierley
Journal:  Nature       Date:  2021-02       Impact factor: 49.962

Review 2.  The Kobe University Human Intestinal Microbiota Model for gut intervention studies.

Authors:  Namiko Hoshi; Jun Inoue; Daisuke Sasaki; Kengo Sasaki
Journal:  Appl Microbiol Biotechnol       Date:  2021-03-15       Impact factor: 4.813

3.  Ulcerative colitis: an update.

Authors:  Jonathan P Segal; Jean-Frédéric LeBlanc; Ailsa L Hart
Journal:  Clin Med (Lond)       Date:  2021-03       Impact factor: 2.659

Review 4.  Treatments of inflammatory bowel disease toward personalized medicine.

Authors:  Ki-Uk Kim; Jisu Kim; Wan-Hoon Kim; Hyeyoung Min; Chang Hwan Choi
Journal:  Arch Pharm Res       Date:  2021-03-24       Impact factor: 4.946

5.  Association Between Ex Vivo Human Ulcerative Colitis Explant Protein Secretion Profiles and Disease Behaviour.

Authors:  R M Corcoran; P MacDonagh; F O'Connell; M E Morrissey; M R Dunne; R Argue; J O'Sullivan; D Kevans
Journal:  Dig Dis Sci       Date:  2022-03-14       Impact factor: 3.199

6.  Oral Administration of Cryptotanshinone-Encapsulated Nanoparticles for the Amelioration of Ulcerative Colitis.

Authors:  Li Zhang; Longfei Yu; Yueguang Wei
Journal:  Cell Mol Bioeng       Date:  2021-10-26       Impact factor: 2.321

7.  Choroid plexus volumetrics and brain inflammation in multiple sclerosis.

Authors:  Navid Manouchehri; Olaf Stüve
Journal:  Proc Natl Acad Sci U S A       Date:  2021-10-05       Impact factor: 11.205

8.  Telomere dysfunction instigates inflammation in inflammatory bowel disease.

Authors:  Deepavali Chakravarti; Rumi Lee; Asha S Multani; Andrea Santoni; Zachery Keith; Wen-Hao Hsu; Kyle Chang; Laura Reyes; Asif Rashid; Chang-Jiun Wu; Jun Li; Jiexin Zhang; Hong Seok Shim; Krishna Chandra; Pingna Deng; Denise J Spring; Ole Haagen Nielsen; Lene Buhl Riis; Kavya Kelagere Mayigegowda; Sarah E Blutt; Jianhua Zhang; Mamoun Younes; Andrew DuPont; Selvi Thirumurthi; Eduardo Vilar; Mary K Estes; Simona Colla; Noah F Shroyer; Ronald A DePinho
Journal:  Proc Natl Acad Sci U S A       Date:  2021-07-20       Impact factor: 11.205

Review 9.  Targeting JAK/STAT signaling pathways in treatment of inflammatory bowel disease.

Authors:  Liang Wang; Yan Hu; Baohui Song; Yongjian Xiong; Jingyu Wang; Dapeng Chen
Journal:  Inflamm Res       Date:  2021-07-01       Impact factor: 4.575

10.  Exosomal MicroRNA-181a Derived From Mesenchymal Stem Cells Improves Gut Microbiota Composition, Barrier Function, and Inflammatory Status in an Experimental Colitis Model.

Authors:  Li Gu; Feng Ren; Xianrui Fang; Lianwen Yuan; Ganglei Liu; Shalong Wang
Journal:  Front Med (Lausanne)       Date:  2021-06-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.